With a market cap of $181.8 billion, Amgen Inc. (AMGN) is a global biotechnology company that discovers, develops, ...

Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m. ET on Thursday, June 4, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, ...

Amgen Inc.’s AMGN Japanese partner Kissei Pharmaceutical Co., Ltd. said it has started information-sharing activities in ...

NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

The U.S. Food and Drug Administration on Friday approved an Amgen Inc drug for non-small cell lung cancer with a specific mutation in a gene known as KRAS in patients whose disease has worsened after ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation.